NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Sep 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
FOSCAVIR (foscarnet sodium) by Bayer is mechanism of action foscarnet exerts its antiviral activity by a selective inhibition at the pyrophosphate binding site on virus-specific dna polymerases at concentrations that do not affect cellular dna polymerases. First approved in 1991.
Drug data last refreshed 26m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FOSCAVIR (foscarnet sodium) is an intravenous antiviral agent approved in 1991 that selectively inhibits virus-specific DNA polymerases without requiring viral kinase activation. It is used to treat cytomegalovirus (CMV) infections and herpes simplex virus (HSV) in immunocompromised patients, particularly those with HIV/AIDS or organ transplant recipients. The drug's unique mechanism allows activity against thymidine kinase-deficient viral strains resistant to conventional antivirals.
LOE Approaching
With LOE approaching and moderate competitive pressure (30/100), the brand team is likely small and focused on defending niche indications rather than growth.
Mechanism of Action
Mechanism of Action Foscarnet exerts its antiviral activity by a selective inhibition at the pyrophosphate binding site on virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases. Foscarnet does not require activation (phosphorylation) by thymidine kinase or…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on FOSCAVIR offers limited career growth potential given the product's LOE-approaching status and zero linked job postings, but provides deep expertise in niche virology, complex patient management, and healthcare economics in specialty hospital settings. This role suits professionals seeking stability in a mature product over high-growth opportunities, with emphasis on defending market share and optimizing reimbursement in declining markets.
Product Manager
Worked on FOSCAVIR at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.